Products and Services

OINDP development specialist Nanopharm, which was acquired by Aptar Pharma in 2019, and functional respiratory imaging (FRI) company Fluidda are teaming up to help sponsors of ANDAs for inhaled drugs for asthma and COPD avoid… Read more . . .

CDMO MedPharm has announced that it will provide formulation and delivery development services for Swiss startup Mosanna Therapeutics’ MOS-118 potassium channel blocker, with the goal of advancing a nasal spray formulation into clinical development for… Read more . . .

Device maker H&T Presspart has partnered with CRO OzUK in order to offer complete development services for metered dose inhalers to H&T Presspart customers. OzUK, which specializes in MDIs and other liquid-based OINDPs, will provide formulation… Read more . . .

OINDP testing equipment maker Copley Scientific has announced the launch of the EnviroMate benchtop environmental control chamber, which is designed to reduce variability in OINDP testing that can occur due to inconsistent temperature, humidity, and electrostatic… Read more . . .

Device maker Nemera has announced the opening of its new headquarters building in Lyons, France. According to the company, the new BREEAM-certified building will also be home to the company’s European innovation teams. Nemera also… Read more . . .

Aptar Pharma said that it has acquired US-based design firm Metaphase Design Group and will integrate the company into its subsidiary Noble, which Aptar acquired in 2019. Noble launched its Human Factors Plus (HF+) services… Read more . . .

The University of Glasgow announced that Innovate UK has awarded a university spinout, Acu-Flow, £1 million for development of the company’s Nebu-Flow surface acoustic wave nebulizer technology. The University said that its researchers will work… Read more . . .

Aptar Pharma announced that it has acquired worldwide rights to Pharmaxis’ high payload Orbital dry powder inhaler. In August 2021, the company said that it had acquired an option to purchase the rights to the Orbital… Read more . . .

According to Inhalation Sciences (ISAB), the FDA will provide up to $500,000 over two years to fund a study intended to validate ISAB’s DissolvIt in vitro lung simulation model for dissolution testing of inhaled drugs.… Read more . . .